Ovid Therapeutics IncOVID
Price$2.43

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $1.6M+179.7% YoYTTM through 30 Jun 2026
Net Income -$34.5MTTM through 30 Jun 2026
Free Cash Flow -$54.8MTTM through 30 Jun 2026

Margins

Current
Gross Margin0.0%
Operating Margin-3,686.5%
Net Margin-2,178.8%

Returns

-12.2%ROE
-10.7%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio10.17x
Net Debt-$165.6Mnet cash position
Cash & Equivalents$11.3M

Quality Metrics

Altman Z-Score12.28
Piotroski F-Score3 / 9
FCF Margin-3,463.4%
Earnings-Beat Rate50.0%

Multi-Year Trend

Revenue
'21'22'23'24'25
FY2025: $7.3M
Diluted EPS
'20'21'22'23
FY2023: $-0.74

Dividend

No dividend

Capital Allocation

Capex Intensity3.3%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.